Equities

Royalty Pharma PLC

Royalty Pharma PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)27.99
  • Today's Change-0.22 / -0.78%
  • Shares traded1.78m
  • 1 Year change+2.08%
  • Beta0.4633
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Income statement Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
REVENUE AND GROSS PROFIT
Total revenue2,3552,2372,289
OPERATING EXPENSES
Cost of revenue total------
Selling, general and admin. expenses, total250227183
Depreciation/amortization05.6723
Unusual expense(income)06160
Other operating expenses, total561904453
Total operating expense8621,930859
Operating income1,4923071,431
Other, net(22)(15)(5.68)
INCOME TAXES, MINORITY INTEREST AND EXTRA ITEMS
Net income before taxes1,7002301,241
Provision for income taxes000
Net income after taxes1,7002301,241
Minority interest(565)(187)(621)
Net income before extra. Items1,13543620
Total extraordinary items------
Net income1,13543620
Inc.avail. to common excl. extra. Items1,13543620
Inc.avail. to common incl. extra. Items1,13543620
EPS RECONCILIATION
Basic/primary weighted average shares448438415
Basic/primary eps excl. extra items2.540.101.49
Basic/primary eps incl. extra items2.540.101.49
Dilution adjustment393----
Diluted weighted average shares603438415
Diluted eps excl. extra items2.530.101.49
Diluted eps incl. extra items2.530.101.49
COMMON STOCK DIVIDENDS
DPS - common stock primary issue0.800.760.68
Gross dividend - common stock358333285
PRO FORMA INCOME
Pro forma net income------
Interest expense, supplemental187188166
SUPPLEMENTAL INCOME
Depreciation, supplemental------
Total special items06160
NORMALISED INCOME
Normalized income before taxes1,7008461,241
Effect of special items on income taxes000
Income tax excluding impact of special items000
Normalized income after tax1,7008461,241
Normalized income avail. to common1,135659620
Basic normalized EPS2.541.501.49
Diluted normalized EPS2.531.501.49
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.